Denali Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Denali Therapeutics
DNLI Stock  USD 19.69  1.15  5.52%   
Denali Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Denali Therapeutics' valuation are provided below:
Gross Profit
-420.7 M
Market Capitalization
3.1 B
Enterprise Value Revenue
2.8 K
Earnings Share
(2.78)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental signals for Denali Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of Denali Therapeutics prevailing fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 2.3 B. Enterprise Value is estimated to decrease to about 2.2 B

Denali Therapeutics Total Revenue

330.53 Million

Check Denali Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Denali Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.1 M, Interest Expense of 8.9 M or Selling General Administrative of 127.3 M, as well as many indicators such as Price To Sales Ratio of 9.74, Dividend Yield of 0.0 or PTB Ratio of 2.17. Denali financial statements analysis is a perfect complement when working with Denali Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Denali Stock
Check out the analysis of Denali Therapeutics Correlation against competitors.
For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.

Denali Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets990.7 M1.6 B691.8 M
Slightly volatile
Other Current Liabilities95.4 M90.9 M32.3 M
Slightly volatile
Total Current Liabilities120.9 M117.5 M79.7 M
Slightly volatile
Other Liabilities937.4 K986.7 K27.7 M
Pretty Stable
Property Plant And Equipment Net151.7 M144.5 M50.9 M
Slightly volatile
Accounts Payable13.4 M12.8 M4.4 M
Slightly volatile
Cash194.3 M201.2 M136.2 M
Slightly volatile
Non Current Assets Total615.5 M586.2 M176.2 M
Slightly volatile
Non Currrent Assets Other29.9 M28.5 M8.3 M
Slightly volatile
Other Assets1.091.152.4 M
Pretty Stable
Cash And Short Term Investments773.6 M957.2 M524.6 M
Slightly volatile
Common Stock Total Equity1.5 M1.8 M1.1 M
Slightly volatile
Common Stock Shares Outstanding96.2 M189.1 M69.1 M
Slightly volatile
Liabilities And Stockholders Equity990.7 M1.6 B691.8 M
Slightly volatile
Non Current Liabilities Total93 M48.6 M72.4 M
Pretty Stable
Capital Surpluse1.9 B1.8 B823.1 M
Slightly volatile
Other Current Assets18.3 M34.4 M12.9 M
Slightly volatile
Other Stockholder Equity3.3 B3.2 B1.1 B
Slightly volatile
Total Liabilities213.9 M166.2 M152.1 M
Slightly volatile
Property Plant And Equipment Gross214.5 M204.3 M63.3 M
Slightly volatile
Preferred Stock Total Equity218.3 M401 M238.1 M
Slightly volatile
Total Current Assets795.3 M994.1 M540.4 M
Slightly volatile
Common Stock1.6 M2 M1.1 M
Slightly volatile
Property Plant Equipment44.6 M85.7 M36.4 M
Slightly volatile
Net Receivables4.3 M2.5 M2.7 M
Slightly volatile
Short Term Investments643.7 M756 M441 M
Slightly volatile
Non Current Liabilities Other6.1 M6.5 M24.2 M
Pretty Stable
Net Invested Capital938.2 M1.4 B731.5 M
Slightly volatile
Net Working Capital815.1 M876.6 M611 M
Slightly volatile
Deferred Long Term Liabilities4.7 M5.3 M5.7 M
Slightly volatile
Capital Stock1.7 M2 M1.5 M
Slightly volatile
Short Term Debt6.8 M10.8 M13.5 M
Slightly volatile
Short and Long Term Debt Total48.9 M43.8 M65.4 M
Slightly volatile
Capital Lease Obligations48.2 M43.8 M65.1 M
Slightly volatile

Denali Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization8.1 M10.3 M5.4 M
Slightly volatile
Selling General Administrative127.3 M121.3 M48.5 M
Slightly volatile
Other Operating Expenses296 M560.4 M213.6 M
Slightly volatile
Research Development237.1 M455.9 M171 M
Slightly volatile
Cost Of Revenue6.7 M7 M39.8 M
Pretty Stable
Total Operating Expenses296 M560.4 M213.6 M
Slightly volatile
Net Interest Income78 M74.3 M19 M
Slightly volatile
Interest Income78 M74.3 M19.4 M
Slightly volatile
Reconciled Depreciation10.1 M10.3 M6.8 M
Slightly volatile
Non Operating Income Net Other7.8 M4.1 M8.6 M
Slightly volatile
Selling And Marketing Expenses13.4 M15.1 M16.4 M
Slightly volatile

Denali Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock16.5 M17.4 M70.3 M
Pretty Stable
Stock Based Compensation124.2 M118.3 M44.5 M
Slightly volatile
Other Cashflows From Financing Activities14.9 M15.7 M42.5 M
Slightly volatile
Depreciation8.1 M10.3 M5.4 M
Slightly volatile
Capital Expenditures10.1 M18.3 M8 M
Slightly volatile
Total Cash From Financing Activities584.8 M556.9 M211.9 M
Slightly volatile
End Period Cash Flow195.3 M203 M136.9 M
Slightly volatile
Change To Netincome114.6 M109.2 M42.8 M
Slightly volatile
Begin Period Cash Flow195.5 M148 M125.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.7410.2623.7864
Pretty Stable
Days Sales Outstanding4.134.3417.1884
Slightly volatile
Stock Based Compensation To Revenue0.280.290.3997
Slightly volatile
Capex To Depreciation1.932.049.9545
Slightly volatile
EV To Sales9.510.022.9593
Pretty Stable
Payables Turnover0.521.020.6935
Slightly volatile
Sales General And Administrative To Revenue0.340.360.4683
Pretty Stable
Research And Ddevelopement To Revenue1.41.471.8856
Pretty Stable
Capex To Revenue0.04280.0450.0837
Pretty Stable
Cash Per Share5.535.8210.6355
Slightly volatile
Days Payables Outstanding3513702 K
Slightly volatile
Current Ratio14.59.7312.0006
Very volatile
Receivables Turnover91.3386.9837.5519
Slightly volatile
Debt To Equity0.0840.04560.1318
Slightly volatile
Capex Per Share0.110.09670.4784
Slightly volatile
Revenue Per Share1.122.171.4868
Pretty Stable
Interest Debt Per Share0.330.270.2889
Slightly volatile
Debt To Assets0.06260.04080.0956
Slightly volatile
Graham Number9.9611.2112.2329
Slightly volatile
Short Term Coverage Ratios70.9879.8687.1657
Slightly volatile
Days Of Payables Outstanding3513702 K
Slightly volatile
Ebt Per Ebit1.031.00.9672
Pretty Stable
Total Debt To Capitalization0.07610.04380.1136
Slightly volatile
Debt Equity Ratio0.0840.04560.1318
Slightly volatile
Quick Ratio14.539.7312.0196
Very volatile
Net Income Per E B T0.80.90.9805
Slightly volatile
Cash Ratio1.871.975.442
Slightly volatile
Days Of Sales Outstanding4.134.3417.1884
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.171.21.1148
Slightly volatile
Fixed Asset Turnover3.085.314.1689
Slightly volatile
Debt Ratio0.06260.04080.0956
Slightly volatile
Price Sales Ratio9.7410.2623.7864
Pretty Stable
Asset Turnover0.270.260.1897
Pretty Stable

Denali Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.3 B3 B1.9 B
Slightly volatile
Enterprise Value2.2 B2.9 B1.8 B
Slightly volatile

Denali Fundamental Market Drivers

Denali Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Denali Therapeutics Financial Statements

Investors use fundamental indicators, such as Denali Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Denali Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue-53.9 M-51.2 M
Cost Of Revenue7 M6.7 M
Stock Based Compensation To Revenue 0.29  0.28 
Sales General And Administrative To Revenue 0.36  0.34 
Research And Ddevelopement To Revenue 1.47  1.40 
Capex To Revenue 0.05  0.04 
Revenue Per Share 2.17  1.12 
Ebit Per Revenue(0.54)(0.56)

Currently Active Assets on Macroaxis

FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
CSANCosan SA ADR
RKTRocket Companies
When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:
How To Invest In Denali
Details
Is Denali Stock a good investment?
Details
What is Denali Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Denali Therapeutics Correlation against competitors.
For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is there potential for Biotechnology market expansion? Will Denali introduce new products? Factors like these will boost the valuation of Denali Therapeutics. Projected growth potential of Denali fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.78)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.27)
Return On Equity
(0.44)
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Denali Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Denali Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Denali Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY